Millions of Medicare beneficiaries waiting on approval for prescription drugs could see their wait times shrink dramatically under a proposed federal rule that would force drug plans to answer standard prior-authorization requests within 72 hours and urgent requests within 24 hours. The Centers for Medicare and Medicaid Services published the proposed rule, designated CMS-0062-P, with a public comment deadline of June 15, 2026, giving stakeholders just 10 days to weigh in on changes that would reshape how quickly patients can access medications.
Tighter drug approval clocks and the gap they close
The proposed timelines represent a sharp compression from the benchmarks CMS set in its earlier, finalized interoperability rule for non-drug services. That rule, CMS-0057-F, required 72 hours for expedited or urgent prior-authorization requests and 7 calendar days for standard requests. Under the new drug-specific proposal, the standard window drops from 7 calendar days to 72 hours, and the urgent window tightens from 72 hours to 24 hours. That difference matters most for patients whose physicians flag a prescription as time-sensitive: a 24-hour ceiling replaces what had been a 3-day allowance for comparable non-drug requests.
CMS framed the change in direct terms, proposing that drug prior-authorization decisions arrive no later than 24 hours for urgent requests and 72 hours for standard requests. The agency tied the proposal to broader goals of reducing provider administrative burden and speeding patient access to medications. Plans covering Medicare Advantage prescription drug benefits, standalone Medicare Part D plans, Medicaid managed care organizations, and CHIP managed care entities would all fall under the new requirements if the rule is finalized.
For patients, the compressed timelines could mean the difference between starting a new therapy before a condition worsens and waiting through a weekend or holiday for a plan decision. For prescribers, the proposal promises fewer follow-up calls and appeals generated simply because an initial request sat in limbo. CMS signaled that it sees prior authorization for drugs as uniquely time-sensitive compared with many non-drug services, justifying the stricter clocks.
Interoperability standards that separate ready plans from the rest
Meeting a 24-hour turnaround is not simply a staffing question. The proposed rule references HL7 FHIR, Da Vinci implementation guides, and NCPDP standards as the technical backbone for electronic prior-authorization exchanges, according to the CMS fact sheet on the drug standards proposal. Plans that have already adopted these application programming interfaces for non-drug prior authorization under CMS-0057-F have a head start. Their systems can accept structured electronic requests, run automated checks against formulary criteria, and return decisions without manual portal logins or fax-based workflows.
Plans still relying on legacy web portals or phone-based authorization processes face a steeper climb. Automating a 24-hour urgent response requires real-time data exchange between prescriber electronic health records and plan adjudication engines. Without FHIR-based connections, each request may sit in a queue until a human reviewer opens it, increasing the risk of missed deadlines when volumes spike or when requests arrive outside normal business hours.
CMS is explicit that technology is central to compliance. The proposed CMS-0062-P regulation would align drug prior-authorization transactions with the broader interoperability framework the agency has been building across Medicare and Medicaid programs. That alignment is designed to let providers use a single set of electronic tools to initiate, track, and receive determinations, regardless of whether a request involves a medication or a medical service.
In practice, the rule would likely widen the performance gap between plans that have invested in modern interoperability and those that have not. Health plans with mature FHIR APIs could embed prior-authorization checks directly into e-prescribing workflows, returning near-real-time responses for many routine drug requests. Plans still dependent on manual review may struggle to meet the 24-hour urgent standard consistently, especially for complex cases or during staffing shortages.
CMS has signaled that it expects to monitor on-time response rates once any final rule takes effect, using data from standardized electronic transactions to assess whether plans are meeting the new deadlines. Those metrics could become a point of comparison for regulators, beneficiaries, and contracting providers, effectively turning prior-authorization speed into a visible measure of plan performance.
What stakeholders will watch next
The compressed public comment window means stakeholders must react quickly. Provider groups are likely to support faster decisions but may push CMS to ensure that technology requirements do not shift costs onto small practices. Plans may ask for phased implementation or flexibility for particularly complex drug classes, arguing that some determinations cannot be safely automated within 24 hours without adequate clinical data.
Patient advocates are expected to focus on enforcement and transparency. Faster clocks only matter if plans comply, and commenters may urge CMS to pair the timelines with clear penalties for chronic noncompliance and public reporting of plan-level performance. Others may ask the agency to clarify how the standards apply to appeals and reauthorizations, where delays can interrupt ongoing treatment.
As CMS reviews comments after June 15, 2026, the agency will decide whether to adjust the proposed timelines, refine the interoperability specifications, or alter the scope of plans subject to the rule. Whatever changes emerge in a final regulation, the core signal is clear: federal regulators want drug prior authorization to move at the speed of modern data exchange, not at the pace of phone calls and faxes.
Warren Cohen is a finance writer based in Phoenix, Arizona, covering personal finance topics including credit, banking, and beginner investing. He earned his degree in business administration from Arizona State University and began his career working in consumer finance, where he gained direct experience with lending and credit systems. He now writes for personal finance websites and fintech platforms, focusing on clear, practical content that helps readers make informed financial decisions.
